Category: Pharmaceutical Industry
-
“Principles of good litigation are universal”: Novo Nordisk Associate General Counsel Raquel Frisardi
“Whether you are litigating a contract, patent infringement, or a crime – there are certain behaviors as a litigator that get you better results, and I think those are very universal,” Raquel Frisardi told ip fray in an interview during Kisaco’s Patent Litigation Europe Summit.
-
“Limited” UPC impact on global pharma patent strategies, interim licenses debate, “seismic” changes at the PTAB: highlights from Patent Litigation Europe
An overwhelming consensus that life sciences companies prefer to litigate in parallel national courts rather than in the UPC, and an intense debate about the use of interim licenses over arbitration, were among the highlights of the second and third days of Kisaco’s annual Patent Litigation Europe in Amsterdam this week.
-
UPC success rate, EPO convergence debate and changing the “status quo”: day one of Patent Litigation Europe
ip fray breaks down the highlights from the first day of the fourth annual Patent Litigation Summit Europe, which featured a full day agenda dedicated to Unified Patent Court Litigation discussions.
-
Edwards faces heart valve patent infringement suit in District of Delaware
Edwards Lifesciences, an active enforcer of its heart valve technology patents in the Unified Patent Court, is now finding itself on the defending side of a patent infringement suit, filed by Israel-based rival Cardiovalve in the U.S.
-
Bayer adds to COVID patent wars: sues Pfizer/BioNTech, Moderna, J&J over mRNA technology
Bayer’s Monsanto has sued Pfizer/BioNTech, Moderna, and Johnson & Johnson over the alleged infringement of a patent related to gene sequencing technology through their COVID-19 vaccinations.
-
China’s top court grants Novo Nordisk win over key Ozempic patent
China’s Supreme People’s Court has upheld a lower court’s decision recognizing the validity of Novo Nordisk’s compound patent related to semaglutide, which is found in the company’s blockbuster drugs Ozempic, Wegovy, and Rybelsus.
-
Novo Nordisk suffers another loss in efforts to extend key Ozempic patent in Brazil
Brazil’s Superior Tribunal de Justiça has issued its first-ever decision on patent term adjustment, ruling that Novo Nordisk’s request to extend its Ozempic-related patent is unconstitutional because a drugmaker’s rights to a patent term cannot override society’s rights to affordable medicine.
-
Abbott regains key patent from now-settled Dexcom dispute as EWCA issues rare patent revocation reversal
The England & Wales Court of Appeal has reversed a lower court’s decision to revoke a patent asserted in Abbott’s now-settled global patent dispute with Dexcom, handing the continuous glucose monitor device maker another key win.
-
Double jeopardy takes down Sanofi’s cabazitaxel use patent as UPC’s Munich LD revokes after EPO BoA affirmance
Lawyers representing generics makers welcomed the UPC’s decision to revoke the patent regardless of a prior EPO decision to the contrary.
-
Teva removes more than 200 patents from U.S. FDA’s Orange Book: win for FTC
Following President Trump’s promise to lower the cost of drugs and a United States Federal Trade Commission investigation into a patent portfolio owned by Teva, the Israeli pharma company has asked the Food and Drug Administration to remove more than 200 improper patent listings related to asthma, diabetes, and COPD drugs, and epinephrine autoinjectors, from…